steroids was the same in the two groups [5] . Finally, the addition of azathioprine to oral prednisolone seemed to be associated with an improved clinical outcome [6] .
A recent single-center study from UK retrospectively evaluated 24 patients with moderate-to-severe and active GO, who were treated concomitantly with intravenous glucocorticoids and a steroid-sparing agent, in most cases (23 of 24 patients), methotrexate (20-25 mg per week orally or subcutaneously, with folic acid supplementation, given for an average of 13 months); in the case of an inadequate response, a second and a third steroid-sparing agent (most commonly cyclosporine, but also, in a few cases, azathioprine or rituximab) were added [7] . The results of this study showed that the mean cumulative dose of intravenous methylprednisolone (2.72 g) required to inactivate GO was lower than the 4.5-g cumulative dose recommended by recent guidelines (4.5 g), and in nine patients (38%) was ≤ 1.5 g [7] . Most patients had a favorable treatment outcome in terms of regression of inflammatory changes, but three patients had to withdraw methotrexate because of impaired liver function tests, chronic cough, and recurrent cystitis [7] .
Although interesting in principle, this study has several limitations, essentially bound to its retrospective nature. The series is small, duration of GO was rather long, detailed information on baseline as well as on treatment-driven changes in exophthalmos, diplopia and overall severity is lacking, and, most importantly, a control group of patients treated with intravenous methylprednisolone alone is missing. Because the 24 patients included in the study were extracted from a larger series of 104 patients, probably an adequately matched group of patients given intravenous methylprednisolone alone might have been added for comparison. Therefore, this study suggests, but does not prove that this combination drug regimen is steroid sparing. This criticism underscores the need for large, multicenter, adequately powered, randomized clinical trials.
The field of the management of GO has witnessed recent important developments, involving the use of biological, such as rituximab, teprotumumab, tocilizumab, and the results of ongoing studies are eagerly awaited, because positive results need to be replicated [8] . These novel drugs might revolutionize the approach to this disfiguring disease by targeting pathogenic mechanisms of GO. In the meanwhile, studies performed using "old" treatments, such as glucocorticoids, and aimed at optimizing the treatment outcome by balancing efficacy, tolerability, durability, costs are welcome, as in this case.
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